Kornimate/medical-research-clean huggingface dataset:
efficacy of deep transcranial magnetic stimulation in patients with opioid use disorder

Conditions: Opioid Use Disorder

Summary: deep tms to the left dorsolateral prefrontal cortex intervention to reduce craving and recurrent opioid use among patients with opioid use disorder who are abstinent for at least one week.

the participants will undergo baseline assessments, including rating scales and urine opioid metabolite tests. the participants will receive one of two treatments: high-frequency (10hz, 3000 pulses per session) dtms using a double cone coil targeting the left dorsolateral prefrontal cortex or sham stimulation. each treatment will be preceded by a short-guided imagery (2-3 min) design to activate the relevant brain circuitry (provocation of symptoms may increase the response rate to deep tms as was evident in the treatment of ptsd, cigarette smoking, and ocd). dtms sessions will be conducted 10 times per week for 2 weeks, for 20 sessions. 8 weeks of patient follow-up, including clinical visits at weeks 0, 2, and 8. during this phase, subjective and objective measures of opioid use (self-report and analysis of urine samples for opioid metabolite) will be collected. following the completion of the main part by the individual, an "open-label" treatment using the same parameters of the experiment will be offered (regardless of the treatment group).

Eligibility criteria:
inclusion criteria: * age 18- 65 * clinical diagnosis of opioid use disorder exclusion criteria: * currently pregnant or breastfeeding * mental retardation, bipolar disorder, any psychotic disorder * neurological diseases such as epilepsy, ischemic stroke, multiple sclerosis * history of head trauma that resulted in loss of consciousness for ≥5 minutes and retrograde amnesia for ≥30 minutes (self-reported history) * any history of seizures other than febrile childhood seizures (self-reported history) * clinically significant hearing impairment * having any prosthesis, such as an implant and pacemaker. * illiteracy

Keywords: transcranial magnetic stimulation opioid use disorder
polyester patch in massive rotator cuff repair improves healing

Conditions: Rotator Cuff Tear

Summary: the purpose of this study was to assess the impact and potential advantage of a novel synthetic patch augmentation in repair of massive rotator cuff (rc) tears, using clinical and radiological approaches. the investigators hypothesized that implanting this patch will improve individual shoulder function, while reducing re-tear rates compared to the current literature.

to evaluate this, patches were implanted into 54 shoulders and prospectively followed up clinically and radiologically.

Eligibility criteria:
inclusion criteria: * inclusion criteria were age greater 18 years and a rc tear involving at least two tendons, presenting a massive rc-tear as described by gerber et al. exclusion criteria: * we excluded patients older than 75, fatty infiltration grade 4 according to goutallier, re-ruptures of former repairs and cases with severe osteoarthritis.

Keywords: arthroscopic rotator cuff repair patch augmentation
treatment of severe alcoholic hepatitis with corticoids plus n acetyl cysteine versus corticoids alone

Conditions: Alcoholic Hepatitis

Summary: 35% of acute alcoholic hepatitis patients (aah) do not respond to corticoids and died after 6 months. chronic alcohol abuse depletes glutathione in the hepatocytes and makes the latter more sensitive to excessive tnfα levels. re-establishment of a stock of antioxidants by administration of a precursor (n-acetyl cysteine, nac) in combination with corticoids (c) could make the hepatocytes more resistant and improve survival. the investigators' study's primary endpoint was improvement of survival at 6 months. the secondary endpoints were survival at 1 and 3 months, tolerance of nac and a drop in blood bilirubin levels at d7

aah patients (maddrey score \> 32 and compatible histological results) should centrally randomized into the c-nac or c groups. both groups received 4 weeks of prednisolone treatment, plus nac for the combination therapy group (d1: 150, 50 and 100 mg/kg in 250, 500 and 1000 ml of 5% glucose-saline (g5%) respectively, at t=30 minutes, 4 and 16 hours; d2 to d5, 100 mg/kg in 1000 ml of g5%). group c received 1000 ml of g5%, d1-5

Eligibility criteria:
inclusion criteria: * patient consent * chronic alcohol intake in the last 3 to 6 months * maddrey score ≥ 32 * liver histology compatible exclusion criteria: * hepato renal syndrome * hepatocarcinoma * recent variceal haemorrhage * recent bacterial infections * other liver diseases associated (hcv, hbv, hemochromatosis, aih) * cancers or cardiac and respiratory, hiv infection * nac allergy * no patient consent * acetaminophen intoxication

Keywords: acute alcoholic hepatitis cirrhosis alcohol alcoholic liver disease
evaluation of the quantra system in a surgical oncological population

Conditions: Blood Loss, Surgical

Summary: this study will monitor coagulation parameters during the perioperative course of cancer surgical procedures using the quantra system with the qplus cartridge.

the quantra system is a fully integrated and automated in vitro diagnostic device which uses seer sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. the quantra qplus cartridge was developed to monitor hemostasis during major surgical procedures in adult patients. the cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed iin parallel yielding six parameters that depict the functional status of a patient's coagulation system. the oncologic surgical population presents unique challenges to providers who must distinguish between a cancer patient's increased tendency toward both thrombosis and hemorrhage. this single site prospective observational study in oncologic patients will give an insight into the coagulation status of critically ill cancer patients.

Eligibility criteria:
inclusion criteria: * subject is \>= 18 years * subject is diagnosed with cancer and is scheduled for surgical resection * subject is willing to participate, and he/she or a legally authorized representative (lar) has signed a consent form * surgical procedure to be performed has an anticipated blood loss (\>500ml) based on historical data exclusion criteria: * subject is younger than 18 years * subject or a subject's lar is unable to provide written informed consent * subject is undergoing an emergent procedure. * subject is pregnant, has active liver disease, or severe renal dysfunction (creatinine clearance (crcl)\<30 ml/min) * subject has an extremely low platelet count (\<40,000/ul) * subject is currently enrolled in a distinct study that might confound the results of the proposed study * subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks

Keywords: viscoelastic testing coagulation quantra hemostasis
evaluation of single-unit implant-supported prostheses survival using cocr prosthetic abutments: prospective observational study

Conditions: Missing Teeth; Prosthesis Survival

Summary: the aim of the study is to prospectively evaluate the survival of jjgc cobalt-chromium (cocr) prosthetic abutments in single-unit implant-supported prostheses, to confirm the long-term safety and performance of the devices.

the cobalt-chromium prosthetic abutments are designed to be installed between the implant and prosthesis. cocr abutment coping, cocr abutment for crown set, block and cares® are devices with indication for prostheses. data from the scientific literature support the safety and intended performance of these abutments. an observational clinical study design was chosen to augment the clinical data derived from the use of these devices in accordance with the ifu (instruction for use) in the daily clinical practice setting, as well as to assess the long-term prosthetic survival rate.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients who had gm dental implants from jjgc installed at the ilapeo college, between 2018 and 2022 * patients who are using a healing abutment or cover screw and are able to install single-unit, screwed or cemented prostheses, in the maxilla or mandible, which require abutments with greater transmucosal height (due to reduced interocclusal height and/or bone loss) * patients presenting antagonist teeth to the implant region exclusion criteria: * patients presenting contraindications according to the ifu (instructions for use) * patients who require the installation of more than 3 single-unit prostheses with cocr abutments.

Keywords: dental implants dental prosthesis
antiproteinuric efficacy of losartan potassium in patients with non-diabetic proteinuric renal diseases (0954-213)

Conditions: Renal Disorder

Summary: antiproteinuric efficacy of losartan potassium in patients with non-diabetic proteinuric renal diseases.


Eligibility criteria:
inclusion criteria: * males or females at least 18 years of age with non-diabetic proteinuric renal diseases
effectiveness of an exercise protocol on alteration of knee joint position sense in futsal players

Conditions: Proprioceptive Disorders; Knee Injuries; Athletic Injuries

Summary: this research presents a randomized clinical trial which evaluates the effectiveness of an exercise protocol on the knee-joint repositioning in futsal players related to a post-match muscle fatigue. our hypothesis is the improvement of sensation in a knee in joint position before and after the match when performing our exercise program.


Eligibility criteria:
inclusion criteria: must have three years of experience in futsal must be licensed players exclusion criteria: lower limb injuries
evaluation of the treatment with klacid®sr in patients with lower respiratory tract infection

Conditions: Tracheitis; Tracheobronchitis; Bronchitis; Chronic Bronchitis; Community-acquired Pneumonia

Summary: the aim of this post-marketing observational study (pmos) is to describe the relief of symptoms, tolerability and compliance of treatment with klacid®sr in a dose 1000 mg once daily in patients with lower respiratory tract infection or in patients with acute exacerbation of chronic bronchitis (aecb) or mild community-acquired pneumonia (cap).

this pmos will be conducted in a prospective, open-label, single-country, multicenter format. the investigational sites will be consulting rooms of gps (general practitioner), pneumologists and centers with experience in the treatment of patients with lower respiratory tract infection, aecb (acute exacerbation of chronic bronchitis) and cap (mild community-acquired pneumonia). since this will be a pmos, klacid®sr will be prescribed in usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. the decision to prescribe or not prescribe klacid®sr would be taken prior to entry of a subject in the study. follow-up of patients should enable two patient visits during this period. screening/inclusion visit will be performed when the decision to start the treatment with klacid®sr is made. inclusion of patient in the study will succeed at day 0 (s/i visit). the second visit will follow 10 - 16 days after the screening/inclusion visit.

Eligibility criteria:
inclusion criteria: * men, women at least 18 years old * with acute tracheitis, * acute tracheobronchitis, * acute bronchitis, * mild community-acquired pneumonia or * acute exacerbation of chronic bronchitis exclusion criteria: * patients with known hypersensitivity to macrolide antibiotics * patients with documented renal impairment (creatinine clearance under 30 ml/min). * patients with documented liver parenchyma impairment (ast, alt and gmt \> 3x higher level in comparison with the norm) * concomitant therapy with the following drugs: astemizole, cisapride, colchicine, pimozide, terfenadine and ergotamine or dihydroergotamine * pregnancy * breast feeding

Keywords: treatment with klacid®sr tracheitis tracheobronchitis bronchitis chronic bronchitis community-acquired pneumonia
assessment of frailty in elderly patients with advanced cancers

Conditions: Cancer

Summary: this study is looking at the feasibility of performing frailty assessments on elderly patients with advanced cancers

this study is primarily looking to see if it is feasible to assess frailty in patients age 70 years and above with advanced cancers. it is also evaluating whether there may be any correlation between these assessments and toxicity and treatment and outcome. the assessments include: frailty score, nutritional assessment, comorbidity score and quality of life. in addition sarcopenia will be assessed using timed walk, grip strength and muscle mass measurement from imaging performed as part of routine clinical care. the assessments will be performed at baseline, week 12 and week 24. there is the option for patients to also donate blood samples for research purposes.

Eligibility criteria:
inclusion criteria: * histological diagnosis of advanced carcinoma - not suitable for curative treatment * age 70 years or over * seen by an oncologist for consideration of palliative systemic medical therapy and decision regarding management already made * who performance status 0-2 * written informed consent exclusion criteria: * hepatocellular cancer * prostate cancer * breast cancer
the reliability and validity of the figure of 8 walk test and double task figure of 8 walk test in persons with stroke

Conditions: Stroke

Summary: the validity of the dual-task f8w test in predicting falls in older adults has been confirmed. as far as we know, there are no studies evaluating the validity and reliability of the dual-task f8w test in stroke patients. therefore, the aim of the study is to evaluate the validity and reliability of the f8w and dual-task f8w test in stroke patients.

recently, the validity and reliability of assessment tools in which two tasks are performed simultaneously have been investigated. although the utility of dual-task assessments in assessing falls in neurological diseases is uncertain, the reliability of dual-task assessments involving walking has shown quite good results. stroke survivors have decreases in one or both (locomotor and cognitive) performances while walking and simultaneously performing a cognitive task. the tasks selected in dual-task evaluations may affect dual-task interactions, therefore, tasks that are compatible with daily living activities should be used in dual-task evaluations. a previous study confirmed the validity of the dual-task f8w test in predicting falls in older adults. because of this reaason, stroke patients aged 50 and over will be included in the study.

Eligibility criteria:
inclusion criteria: * being 50 years of age and older, * having only one unilateral stroke at least 6 months prior to the study, * being medically stable, * being able to walk at least 10 meters with a cane or independently, * getting 24 points or more from the standardized mini-mental test', * being to be able to perform the cognitive task (subtraction) to be given during the evaluations. exclusion criteria: * the presence of additional orthopedic, neurological or cardiovascular diseases that may affect balance and walking, * uncorrected vision and hearing problems.
investigation of a link between heart rate variability and frailty in geriatric patients

Conditions: Fragility

Summary: the aim of this study is the evaluation of differences in heart rate variability (both time- and frequency-domain) \[a\]: between frail and non-frail patients and \[b\] at the beginning and end of a geriatric therapy which included rehabilitation components. moreover, the suitability of new camera-based technology with regard to measurement of vital signs (heart rate, heart rate variability, respiratory rate) will be evaluated.

frailty is an important geriatric syndrome, which indicates a reduced maximum resilience of patients and their organ system against external stressors. according to fried's classification, frailty comprises of unintentional weight loss, exhaustion, muscle weakness, slowness while walking and low levels of activity. in geriatric patients, frailty is associated with a higher mortality and morbidity. moreover, frailty patients are more often dependent on assistance after hospitalisation than non-frailty patients. during geriatric therapy, geriatric patients are treated with multimodal rehabilitation comprising of activating nursing, physiotherapy, occupational therapy, psychiatric and speech therapy in order to increase mobility and patients' ability to help themselves. success of rehabilitation measures is measured using the geriatric assessment (e.g. barthel index, timed up and go test, mini-mental state examination, geriatric depression scale, measurement of hand power) at the beginning and end of the therapy. this geriatric therapy including the named geriatric assessment is not study-specific and is not prescribed by a study protocol, but is a routine treatment for frail patients. apart from these routinely used tests, recent literature indicated that heart rate variability, which can be easily measured with an ecg, could be an indicator for frailty. beyond the medical problem whether heart rate variability can be used as a surrogate parameter for frailty, this study also has a technical aspect. in biomedical engineering, non-contact monitoring of vital signs has been an important and promising development in the last decade. therefore, this study will also investigate if camera-based technologies such as photoplethysmography imaging (ppgi) and infrared thermography (irt) can be used in a clinical environment for non-contact measurement of vital signs (heart rate, heart rate variability, respiratory rate) in geriatric patients. in this study, monitoring (with conventional and contactless technologies) should not trigger any observable/examining effect, but is merely a means to the end of observing the already existing hrv (and other vital parameters).

Eligibility criteria:
inclusion criteria: * group 1: aged above 70 if they have typical geriatric multimorbidity, otherwise aged above 80, patient on the geriatric ward in the hospital "franziskhospital aachen" * group 2 (healthy volunteers): aged above 70, healthy and in good physical condition * written informed consent by patient / volunteer exclusion criteria: * inability to consent * pace maker
non-narcotic pain control after acl reconstruction

Conditions: ACL - Anterior Cruciate Ligament Rupture; ACL Injuries

Summary: this is a double-blind randomized controlled trial of standard of care therapy, either oral ketorolac (experimental group) or oral oxycodone (control group) to demonstrate efficacy in reducing the percentage of narcotic doses taken and documenting the number of patients with no exposure to any narcotics (take zero oxycodone) after undergoing primary knee acl reconstruction outpatient surgery.

this is a multi-center, 2 arm, randomized 1:1 controlled trial, with a blinded patient and outcome assessment study. narcotics are currently the standard of care as part multimodal pain control in major joint surgery including aclr. twelve (12) ketorolac (10mg) and twelve (12) oxycodone (5mg) tablets will be shrouded in identical capsules designed for blinding. the capsules will be dispensed in sealed single-pill release blister packets. the enrolled patients will be randomized by the surgeon. the surgeon, clinical team, and patient will be blinded as to treatment (double-blind study). the rescue medication will be specific to each treatment group, encapsulated for blinding, and in a packet labeled rescue medication. for the experimental group (ketorolac) they will have 12 oxycodone as rescue medication. for the control group (oxycodone) they will have 12 diclofenac as rescue medication. both groups will also be given acetaminophen for the first 72 hours. all medications in our multimodal approach will be provided postoperatively after acl reconstruction to both groups. the primary endpoint will be the percentage reduction in narcotics pills per patient in each group in first 72 hours postoperatively verified from sealed packages.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study * male or female, aged 15-55 years * primary autograft acl surgery * ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts exclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for t the duration of the study * male or female, aged 15-55 years * primary autograft acl surgery * ability to take oral medication and willingness to patriciate in a virtual 1 and 2 week follow-up pill counts

Keywords: acl narcotic use
upper trunk block versus costoclavicular block for arthroscopic shoulder surgery

Conditions: Shoulder Pain; Phrenic Nerve Paralysis

Summary: interscalene brachial plexus block is known as the gold standard for analgesia after shoulder surgery, but limits the use of ipsilateral phrenic nerve paralysis. recently, interest in potential diaphragm-sparing alternative blocks has increased for patients undergoing shoulder surgery.two of these blocks are upper trunk block (utb) and costoclavicular brachial plexus (ccbpb) block. this randomized controlled trial will compare ultrasound-guided utb and ccbpb in patients undergoing arthroscopic shoulder surgery. the main outcome is pain intensity score at 30 minutes after arrival in the post anesthesia care unit (pacu) as measured by a numerical rating scale (nrs) from 0 to 10. the investigators research hypothesis is that utb and ccbpb will result in equivalent postoperative analgesia at 30 minutes in the pacu.


Eligibility criteria:
inclusion criteria: 1. american association of anesthesiologists (asa) physical status i - iii 2. bmi 20 to 35 kg / m2 3. patients scheduled for elective arthroscopic shoulder surgery exclusion criteria: 1. patients who refuse to participate in the study, 2. pre-existing (obstructive or restrictive) lung disease, 3. coagulopathy, 4. sepsis, 5. hepatic or renal insufficiency, 6. pregnancy 7. allergy to local anesthetic drugs, 8. chronic pain condition requiring opioid intake at home, 9. surgery in the neck or infraclavicular region 10. bmi above 40. 11. history of psychiatric diseases needing treatment. 12. failure of nerve block performed in the preoperative block room 13. substance abuse history

Keywords: bupivacaine costoclavicular block upper trunk block